Christopher Holroyd

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Frances Humby, Patrick Durez, Maya H Buch et al. · The Lancet · 2021 · 315 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Felice Rivellese, Anna E. A. Surace, Katriona Goldmann et al. · Nature Medicine · 2022 · 279 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis

Christopher Holroyd, Rakhi Seth, Marwan Bukhari et al. · Lara D. Veeken · 2018 · 178 citations · Full text

Medicine, Immunology, Internal Medicine +11

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 88 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis—Executive summary

Christopher Holroyd, Rakhi Seth, Marwan Bukhari et al. · Lara D. Veeken · 2018 · 75 citations · Full text

Medicine, Immunology, Internal Medicine +11